RT Journal Article
SR Electronic
T1 Search for New Genetic Biomarkers in Poorly Differentiated and Anaplastic Thyroid Carcinomas Using Next Generation Sequencing
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2029
OP 2036
VO 35
IS 4
A1 VLASTA SYKOROVA
A1 SARKA DVORAKOVA
A1 JOSEF VCELAK
A1 ELISKA VACLAVIKOVA
A1 TEREZA HALKOVA
A1 DANIELA KODETOVA
A1 PETR LASTUVKA
A1 JAN BETKA
A1 PETR VLCEK
A1 MARTIN REBOUN
A1 RAMI KATRA
A1 BELA BENDLOVA
YR 2015
UL http://ar.iiarjournals.org/content/35/4/2029.abstract
AB Background: Poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid carcinoma (ATC) are very rare tumors with extremely aggressive behavior. Their comprehensive genetic background is still unclear. Some of the main genetic changes of differentiated thyroid carcinomas, such as mutations in BRAF and RAS genes, as well as changes in CTNNB1, PIK3CA, TP53, AXIN1, PTEN or APC genes leading to the dedifferentiation of the tumors, are described. Materials and Methods: DNAs from fresh frozen thyroid tissues of 3 PDTCs and 5 ATCs were extracted. The next-generation sequencing (NGS) approach was used to target 94 genes involved in cancer. The samples were prepared using a TruSight Cancer panel and sequenced with a MiSeq sequencer. Analysis of variants was performed by the MiSeq Reporter and NextGENe software and stringent criteria for prioritization of the variants were used in the Illumina VariantStudio software. Results: Using NGS, we identified 26 genetic changes in 18 genes, novel variants included. Conclusion: NGS is a useful tool for searching for new variants and genes involved in PDTC and ATC. It seems that each of these rare tumor types has its own specific genetic background. These data could be helpful for recognizing new genetic markers and targets for future personalized therapy.